Table 1.

Patient demographics. Patient characteristics are depicted including CMV and EBV reactivation status. Patients 7, 17, 18 and 27 showed signs of gastroenteritis, which required transient hospitalization in patients 7, 17, and 18, and all four transiently experienced an Uhthoff phenomenon.

	Age	Sex	Diagnosis	Last Therapy before aHSCT	EDSS at aHSCT	CMV Viremia	EBV Viremia
aHSCT_MS_01	38	female	RRMS	Natalizumab	4
aHSCT_MS_02	36	male	RRMS	Fingolimod	5.5
aHSCT_MS_03	53	female	PPMS	Fingolimod	6.5
aHSCT_MS_04	32	female	RRMS	Rituximab	4
aHSCT_MS_05	47	male	PPMS	Rituximab	6.5
aHSCT_MS_06	49	female	PPMS	Rituximab	4
aHSCT_MS_08	30	male	PPMS	Ocrelizumab	4.5
aHSCT_MS_09	48	female	SPMS	Rituximab	6
aHSCT_MS_10	36	female	SPMS	Ocrelizumab	4.5
aHSCT_MS_11	47	male	RRMS	Ocrelizumab	3
aHSCT_MS_12	45	male	SPMS	Rituximab	6.5
aHSCT_MS_13	41	male	PPMS	Ocrelizumab	3
aHSCT_MS_15	54	female	SPMS	Rituximab	5.5
aHSCT_MS_16	33	female	RRMS	Ocrelizumab	4.5
aHSCT_MS_19	43	male	PPMS	Rituximab	6
aHSCT_MS_20	47	male	PPMS	Ocrelizumab	6
aHSCT_MS_22	54	female	SPMS	Rituximab	4.5
aHSCT_MS_24	44	female	SPMS	Rituximab	4
aHSCT_MS_25	44	male	SPMS	Ocrelizumab	3.5
aHSCT_MS_21	25	male	RRMS	Ocrelizumab	2		x
aHSCT_MS_23	43	male	RRMS	Natalizumab	3		x
aHSCT_MS_26	40	female	RRMS	Natalizumab	3.5		x
aHSCT_MS_28	32	female	RRMS	Ocrelizumab	2		x
aHSCT_MS_36	39	female	RRMS	Ocrelizumab	3		x
aHSCT_MS_07	33	female	SPMS	Rituximab	5	x
aHSCT_MS_14	25	male	PPMS	Rituximab	6.5	x
aHSCT_MS_27	51	male	SPMS	Ocrelizumab	4.5	x
aHSCT_MS_31	40	female	RRMS	Ocrelizumab	3.5	x
aHSCT_MS_17	39	female	RRMS	Ocrelizumab	2.5	x	x
aHSCT_MS_18	47	male	RRMS	Natalizumab	4	x	x
aHSCT_MS_32	35	male	RRMS	Ocrelizumab	3	x	x
aHSCT_MS_34	29	female	RRMS	Ocrelizumab	2	x	x